In vitro findings demonstrate YB-1's role in drug resistance in multiple myeloma, indicating potential therapeutic targets to enhance chemoresistance management.
Key Points
This research aims to elucidate the role of YB-1 in proteasome inhibitors resistance in multiple myeloma through RNA 5-methylcytosine modification.
In vitro experiments assessing YB-1 knockdown effects on MM cells
Xenograft models using MM cell lines with YB-1 knockdown in NCG mice
High-throughput sequencing analyses including m5C-Bis-seq, RIP-seq, and RNA-seq
YB-1 knockdown induced increased apoptosis and G2 phase arrest in MM cells under proteasome inhibitors treatment
YB-1 KD significantly reduced tumor burden and improved survival in xenograft models
Restoration of YB-1 expression rescued MM cell survival under proteasome inhibitors treatment, highlighting its role in drug resistance